A prospective, non-interventional, observational, multi-center trial to evaluate compliance and efficacy in mono and combination treatment of candesartan cilexetil(Atacand)/ candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg(Atacand plus) in hypertension

Trial Profile

A prospective, non-interventional, observational, multi-center trial to evaluate compliance and efficacy in mono and combination treatment of candesartan cilexetil(Atacand)/ candesartan cilexetil 16mg, hydrochlorothiazide 12.5mg(Atacand plus) in hypertension

Completed
Phase of Trial: Phase III

Latest Information Update: 30 Nov 2010

At a glance

  • Drugs Candesartan cilexetil; Candesartan cilexetil/hydrochlorothiazide
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Acronyms COMBAT
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Nov 2010 Actual initiation date changed from Jul 2007 to Jun 2007 as reported by ClinicalTrials.gov.
    • 01 Dec 2008 Actual trial completion date identified as August 2008 from ClinicalTrials.gov.
    • 01 Dec 2008 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top